Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25914393 | 1.00 | RIPK1 (0.38) | RIPK1KIF11SMN1; SMN2KCNH2LMNA | |
| SCHEMBL25327487 | 0.99 | RIPK1 (0.38) | RIPK1KIF11SMN1; SMN2KCNH2LMNA | |
| SCHEMBL25326913 | 0.86 | RIPK1 (0.50) | RIPK1KIF11LMNAPDK2 | |
| SCHEMBL30522995 | 0.85 | TACR1 (0.35) | RIPK1 | |
| SCHEMBL25326429 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2KCNH2KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL25327368 | 0.84 | TACR1 (0.41) | KMT2AMEN1 | |
| SCHEMBL25327371 | 0.84 | TACR1 (0.41) | KMT2AMEN1 | |
| SCHEMBL25326792 | 0.84 | TACR1 (0.41) | KMT2AMEN1 | |
| SCHEMBL25325730 | 0.82 | KMT2A (0.44) | SMN1; SMN2KCNH2KMT2AALDH1A1MEN1 | |
| SCHEMBL25913860 | 0.82 | KMT2A (0.44) | SMN1; SMN2KCNH2KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | RIPK1 4782/4885KIF11 2548/4885SMN1; SMN2 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.